Glycigon-M SR Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, designed for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea derivative, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The sustained-release formulation of Glycigon-M SR ensures a gradual release of active ingredients, promoting stable plasma drug concentrations and reducing the frequency of dosing, which may enhance patient compliance. This combination is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. Glycigon-M SR should be used with caution in patients with renal or hepatic impairment, and regular monitoring of blood glucose levels and renal function is recommended. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Hypoglycemia is a potential risk due to the sulfonylurea component, necessitating patient education on symptom recognition and management. Overall, Glycigon-M SR offers an effective therapeutic option for improving glycemic control in type 2 diabetes mellitus when used as part of a comprehensive treatment plan.